Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

BioHiTech Global

DB:46Q
Snowflake Description

High growth potential with worrying balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
46Q
DB
$23M
Market Cap
  1. Home
  2. DE
  3. Commercial Services
Company description

BioHiTech Global, Inc., through its subsidiaries, provides technological, biological, and mechanical engineering solutions for the control, reduction, and/or reuse of organic and municipal waste worldwide. The last earnings update was 138 days ago. More info.


Add to Portfolio Compare Print
  • BioHiTech Global has significant price volatility in the past 3 months.
46Q Share Price and Events
7 Day Returns
-0.8%
DB:46Q
-1.9%
DE Commercial Services
-0.6%
DE Market
1 Year Returns
-
DB:46Q
-32.9%
DE Commercial Services
-20.9%
DE Market
46Q Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
BioHiTech Global (46Q) -0.8% -21.7% - - - -
DE Commercial Services -1.9% -23.9% -35.4% -32.9% -36.8% -47.7%
DE Market -0.6% -18.6% -26.2% -20.9% -25.8% -31.8%
1 Year Return vs Industry and Market
  • No trading data on 46Q.
  • No trading data on 46Q.
Price Volatility
46Q
Industry
5yr Volatility vs Market

46Q Value

 Is BioHiTech Global undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether BioHiTech Global is trading at an attractive price based on the cash flow it is expected to produce in the future. But as BioHiTech Global has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for BioHiTech Global. This is due to cash flow or dividend data being unavailable. The share price is €1.28.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for BioHiTech Global's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are BioHiTech Global's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:46Q PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-09-30) in USD $-0.56
NasdaqCM:BHTG Share Price ** NasdaqCM (2020-04-03) in USD $1.35
Germany Commercial Services Industry PE Ratio Median Figure of 6 Publicly-Listed Commercial Services Companies 94.45x
Germany Market PE Ratio Median Figure of 401 Publicly-Listed Companies 16.57x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of BioHiTech Global.

DB:46Q PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:BHTG Share Price ÷ EPS (both in USD)

= 1.35 ÷ -0.56

-2.43x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioHiTech Global is loss making, we can't compare its value to the DE Commercial Services industry average.
  • BioHiTech Global is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does BioHiTech Global's expected growth come at a high price?
Raw Data
DB:46Q PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -2.43x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
85.1%per year
Europe Commercial Services Industry PEG Ratio Median Figure of 48 Publicly-Listed Commercial Services Companies 1.09x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.17x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for BioHiTech Global, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on BioHiTech Global's assets?
Raw Data
DB:46Q PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-09-30) in USD $-0.08
NasdaqCM:BHTG Share Price * NasdaqCM (2020-04-03) in USD $1.35
Germany Commercial Services Industry PB Ratio Median Figure of 9 Publicly-Listed Commercial Services Companies 2.23x
Germany Market PB Ratio Median Figure of 572 Publicly-Listed Companies 1.44x
DB:46Q PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:BHTG Share Price ÷ Book Value per Share (both in USD)

= 1.35 ÷ -0.08

-17.4x

* Primary Listing of BioHiTech Global.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • BioHiTech Global has negative assets, we can't compare the value of its assets to the DE Commercial Services industry average.

Next steps:

  1. Take a look at BioHiTech Global's forecasted future earnings and revenues from industry analysts to understand how the company is expected to perform in the future against its competitors and the wider market.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through BioHiTech Global's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Commercial Services industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess BioHiTech Global's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Commercial Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Commercial Services industry average (and greater than 0)? (1 check)
  5. BioHiTech Global has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

46Q Future Performance

 How is BioHiTech Global expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
85.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is BioHiTech Global expected to grow at an attractive rate?
  • BioHiTech Global's earnings growth is expected to exceed the low risk savings rate of -0.4%.
Growth vs Market Checks
  • BioHiTech Global's earnings growth is expected to exceed the Germany market average.
  • BioHiTech Global's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:46Q Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:46Q Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts 85.1%
DB:46Q Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 1 Analysts 56.1%
Germany Commercial Services Industry Earnings Growth Rate Market Cap Weighted Average 21%
Germany Commercial Services Industry Revenue Growth Rate Market Cap Weighted Average 2.8%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:46Q Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:46Q Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2021-12-31 14 1 2 1
2020-12-31 9 -4 -4 1
2020-04-05
2019-12-31 5 -8 -8 2
DB:46Q Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-09-30 4 -8 -8
2019-06-30 4 -4 -9
2019-03-31 3 -5 -12
2018-12-31 3 -6 -15
2018-09-30 3 -5 -15
2018-06-30 3 -6 -15
2018-03-31 2 -6 -12
2017-12-31 2 -5 -8
2017-09-30 3 -5 -8
2017-06-30 2 -4 -7
2017-03-31 2 -5 -7
2016-12-31 2 -5 -7

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • BioHiTech Global's earnings are expected to grow significantly at over 20% yearly.
  • BioHiTech Global's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:46Q Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (6 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from BioHiTech Global Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:46Q Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2021-12-31 0.12 0.12 0.12 1.00
2020-12-31 -0.21 -0.21 -0.21 1.00
2020-04-05
2019-12-31 -0.50 -0.50 -0.50 2.00
DB:46Q Past Financials Data
Date (Data in USD Millions) EPS *
2019-09-30 -0.56
2019-06-30 -0.58
2019-03-31 -0.80
2018-12-31 -1.11
2018-09-30 -1.24
2018-06-30 -1.44
2018-03-31 -1.26
2017-12-31 -0.98
2017-09-30 -0.96
2017-06-30 -0.89
2017-03-31 -0.87
2016-12-31 -0.82

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if BioHiTech Global will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess BioHiTech Global's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
BioHiTech Global has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

46Q Past Performance

  How has BioHiTech Global performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare BioHiTech Global's growth in the last year to its industry (Commercial Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • BioHiTech Global does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare BioHiTech Global's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare BioHiTech Global's 1-year growth to the Europe Commercial Services industry average as it is not currently profitable.
Earnings and Revenue History
BioHiTech Global's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from BioHiTech Global Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:46Q Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-09-30 3.93 -8.36 6.86
2019-06-30 3.59 -8.52 7.55
2019-03-31 3.45 -11.93 7.49
2018-12-31 3.36 -15.16 6.74
2018-09-30 3.27 -15.22 6.85
2018-06-30 2.84 -15.40 7.34 -0.40
2018-03-31 2.48 -11.64 7.05 -0.19
2017-12-31 2.42 -8.36 7.19
2017-09-30 2.50 -7.99 6.86 0.24
2017-06-30 2.47 -7.33 5.90 0.88
2017-03-31 2.37 -7.17 5.84 0.90
2016-12-31 2.24 -6.75 5.49 0.90
2016-09-30 2.11 -6.82 5.66 0.87
2016-06-30 1.83 -6.64 5.47 0.80
2016-03-31 1.70 -5.64 4.77 0.71
2015-12-31 1.51 -5.00 4.07 0.70
2015-09-30 1.48 -4.59 3.13 1.07
2015-06-30 1.62 -3.85 2.71 0.90
2015-03-31 1.55 -3.90 2.75 0.76
2014-12-31 1.52 -3.70 2.79 0.58
2014-09-30 2.70 -2.71 3.02
2014-06-30 3.94 -2.44 3.17
2014-03-31 3.69 -1.67 2.48
2013-12-31 3.44 -0.90 1.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if BioHiTech Global has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • BioHiTech Global used its assets less efficiently than the DE Commercial Services industry average last year based on Return on Assets.
  • It is difficult to establish if BioHiTech Global improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess BioHiTech Global's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Commercial Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
BioHiTech Global has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

46Q Health

 How is BioHiTech Global's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up BioHiTech Global's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • BioHiTech Global's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • BioHiTech Global's long term commitments exceed its cash and other short term assets.
Balance sheet
This treemap shows a more detailed breakdown of BioHiTech Global's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is not covered by short term assets, assets are 0.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from BioHiTech Global Company Filings, last reported 6 months ago.

DB:46Q Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-09-30 10.79 37.93 3.43
2019-06-30 9.57 37.84 1.65
2019-03-31 9.59 37.67 1.37
2018-12-31 10.82 37.45 2.41
2018-09-30 3.80 5.80 0.38
2018-06-30 4.97 5.72 1.05
2018-03-31 1.29 10.87 3.22
2017-12-31 -10.39 16.74 0.90
2017-09-30 -16.14 16.70 0.48
2017-06-30 -14.47 14.48 0.15
2017-03-31 -13.11 13.52 0.32
2016-12-31 -11.46 11.53 0.33
2016-09-30 -9.90 9.41 0.18
2016-06-30 -8.42 8.48 0.23
2016-03-31 -6.92 7.28 0.14
2015-12-31 -5.45 5.34 0.04
2015-09-30 -6.15 6.69 0.05
2015-06-30 -4.70 6.01 0.04
2015-03-31 -3.15 4.42 0.04
2014-12-31 -3.15 4.42 0.04
2014-09-30
2014-06-30 -0.03 0.03 0.00
2014-03-31 -0.32 2.45 0.29
2013-12-31 -0.32 2.45 0.29
  • BioHiTech Global's level of debt (351.5%) compared to net worth is high (greater than 40%).
  • BioHiTech Global had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • BioHiTech Global has less than a year of cash runway based on current free cash flow.
  • BioHiTech Global has less than a year of cash runway if free cash flow continues to grow at historical rates of 30.2% each year.
X
Financial health checks
We assess BioHiTech Global's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. BioHiTech Global has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

46Q Dividends

 What is BioHiTech Global's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from BioHiTech Global dividends.
If you bought €2,000 of BioHiTech Global shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate BioHiTech Global's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate BioHiTech Global's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:46Q Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Germany Commercial Services Industry Average Dividend Yield Market Cap Weighted Average of 5 Stocks 5.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 316 Stocks 3.9%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:46Q Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2021-12-31
2020-12-31
2020-04-05
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as BioHiTech Global has not reported any payouts.
  • Unable to verify if BioHiTech Global's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of BioHiTech Global's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as BioHiTech Global has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess BioHiTech Global's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can BioHiTech Global afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. BioHiTech Global has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

46Q Management

 What is the CEO of BioHiTech Global's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frank Celli
COMPENSATION $410,400
AGE 49
TENURE AS CEO 4.7 years
CEO Bio

Mr. Frank E. Celli has been the Chief Executive Officer of BioHiTech Global, Inc. since August 06, 2015 and serves as its Chairman of the Board. Mr. Celli joined BioHiTech America in 2008. Mr. Celli serves as the Chief Executive Officer of Highstar Waste Holding Corp. He serves as an Officer of Entsorga West Virginia. With over 25 years of Waste Industry experience, Mr. Celli has leveraged his knowledge of the traditional waste industry to facilitate the development of the Eco-Safe Digester and BioHiTech Cloud to begin the transformation of the organic waste industry. He was Co-Founder and served as Chief Executive Officer of Interstate Waste Services from October 2000 to November 2006. During his time at Interstate Waste, he was responsible for all aspects of the business including collection, recycling, landfills and emerging technologies. He has been Director of BioHiTech Global, Inc. since August 06, 2015. He also serves as a Director of Entsorga West Virginia. Mr. Celli is also the chairman of the board of Apple Valley Waste Services, Inc. Mr. Celli earned a Bachelors of Science from Pace University’s Lubin School of Business in 1992.

CEO Compensation
  • Frank's compensation has increased whilst company is loss making.
  • Frank's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the BioHiTech Global management team in years:

3.2
Average Tenure
60
Average Age
  • The tenure for the BioHiTech Global management team is about average.
Management Team

Frank Celli

TITLE
Chairman & CEO
COMPENSATION
$410K
AGE
49
TENURE
4.7 yrs

Bob Joyce

TITLE
Chief Operating Officer
COMPENSATION
$679K
AGE
60
TENURE
2.3 yrs

Brian Essman

TITLE
Chief Financial Officer
COMPENSATION
$504K
AGE
60
TENURE
4.4 yrs

Tony Fuller

TITLE
Chief Administrative Officer & Director
COMPENSATION
$74K
AGE
61
TENURE
0.1 yrs

Lisa Giovannielli

TITLE
Marketing Director

Mike Franco

TITLE
Vice President of Sales

Dennis Soriano

TITLE
Director of Business Development and Strategic Relationships
TENURE
4.1 yrs

Richard Galterio

TITLE
Executive Vice President

Mike Schmidt

TITLE
Executive Vice President of Strategic Growth & Initiatives
TENURE
0.7 yrs
Board of Directors Tenure

Average tenure and age of the BioHiTech Global board of directors in years:

4.7
Average Tenure
61.5
Average Age
  • The tenure for the BioHiTech Global board of directors is about average.
Board of Directors

Frank Celli

TITLE
Chairman & CEO
COMPENSATION
$410K
AGE
49

Tony Fuller

TITLE
Chief Administrative Officer & Director
COMPENSATION
$74K
AGE
61
TENURE
3.2 yrs

James Chambers

TITLE
Independent Director
COMPENSATION
$74K
AGE
62
TENURE
11.8 yrs

Bob Graham

TITLE
Independent Director
COMPENSATION
$74K
AGE
60
TENURE
6.5 yrs

Doug VanOort

TITLE
Independent Director
COMPENSATION
$74K
AGE
64
TENURE
4.7 yrs

Harriet Hentges

TITLE
Independent Director
COMPENSATION
$74K
AGE
78
TENURE
4.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
03. Jan 20 Buy Harriet Hentges Individual 24. Dec 19 24. Dec 19 2,000 €1.48 €2,957
10. Oct 19 Buy Frank Celli Individual 08. Oct 19 09. Oct 19 1,361 €1.58 €2,112
08. Oct 19 Buy Frank Celli Individual 04. Oct 19 07. Oct 19 3,639 €1.59 €5,589
01. Oct 19 Buy James Chambers Individual 27. Sep 19 30. Sep 19 17,000 €1.69 €27,974
30. Sep 19 Buy Robert Joyce Individual 26. Sep 19 26. Sep 19 2,000 €1.66 €3,310
X
Management checks
We assess BioHiTech Global's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. BioHiTech Global has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

46Q News

Simply Wall St News

46Q Company Info

Description

BioHiTech Global, Inc., through its subsidiaries, provides technological, biological, and mechanical engineering solutions for the control, reduction, and/or reuse of organic and municipal waste worldwide. The company sells, rents, services, and maintains digesters, which are a data-driven network-based mechanical/biological technology that transforms food waste into nutrient-neutral water that could be disposed of through conventional sanitary sewer systems under the Revolution Series Digester and Eco-Safe Digester names. Its digesters process organic food waste, including vegetables, fruits, meat, fish, poultry, grains, coffee grinds, egg shells, and dairy products. The company also provides BioHiTech Cloud, Cirrus, and Alto mobile applications for digester customers. Its principal customers include producers of food waste. The company serves healthcare, grocery, prison, retail food service, and hospitality industries, as well as governments, conference centers, education centers, and stadiums. BioHiTech Global, Inc. is headquartered in Chestnut Ridge, New York.

Details
Name: BioHiTech Global, Inc.
46Q
Exchange: DB
Founded:
$21,579,357
17,245,344
Website: http://www.biohitech.com
Address: BioHiTech Global, Inc.
80 Red Schoolhouse Road,
Suite 101,
Chestnut Ridge,
New York, 10977,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM BHTG Common Shares Nasdaq Capital Market US USD 18. Aug 2015
DB 46Q Common Shares Deutsche Boerse AG DE EUR 18. Aug 2015
Number of employees
Current staff
Staff numbers
27
BioHiTech Global employees.
Industry
Environmental and Facilities Services
Commercial Services
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/05 23:40
End of day share price update: 2020/04/03 00:00
Last estimates confirmation: 2020/03/31
Last earnings filing: 2019/11/19
Last earnings reported: 2019/09/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.